RxSight (RXST)
(Delayed Data from NSDQ)
$7.55 USD
-0.10 (-1.31%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.55 0.00 (0.00%) 6:16 PM ET
5-Strong Sell of 5 5
F Value D Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, RxSight, Inc. has a market cap of $310.87M, which represents its share price of $7.65 multiplied by its outstanding shares number of 40.64M. As a small-cap company, RXST's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RXST 7.55 -0.10(-1.31%)
Will RXST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXST
FMS vs. RXST: Which Stock Is the Better Value Option?
FMS or RXST: Which Is the Better Value Stock Right Now?
RXST: What are Zacks experts saying now?
Zacks Private Portfolio Services
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Do Options Traders Know Something About RxSight Stock We Don't?
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
Other News for RXST
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors | RXST Stock News
RxSight appoints Raymond Cohen to its board of directors
RXST: Morgan Stanley Downgrades RxSight, Price Target Slashed | RXST Stock News
Morgan Stanley Adjusts RxSight (RXST) Outlook Amid Market Challenges | RXST Stock News
RxSight just downgraded at Morgan Stanley, here's why